Related Experiment Video
Updated: Dec 15, 2025
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
16.1K
Circulating miRNAs as Biomarkers in Aggressive B Cell Lymphomas
Esther E E Drees1, D Michiel Pegtel1
1Amsterdam UMC, Vrije Universiteit Amsterdam, Exosomes Research Group, Department of Pathology, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Trends in Cancer
|July 15, 2020
Summary
Circulating microRNAs (miRNAs) within extracellular vesicles (EVs) show promise as liquid biopsy biomarkers for aggressive B cell lymphoma. These accessible biomarkers can potentially monitor systemic treatment responses, overcoming limitations of traditional tissue biopsies.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- B cell lymphomas are diverse hematological cancers with varied clinical outcomes.
- Current diagnostic and monitoring methods rely on tissue biopsies and imaging, which have limitations for frequent assessment and tracking systemic responses.
- MicroRNAs (miRNAs) are small non-coding RNAs involved in gene regulation, and their aberrant expression is linked to cancer development.
Purpose of the Study:
- To explore the role of miRNAs and extracellular vesicles (EVs) in B cell lymphomagenesis.
- To investigate the potential of circulating miRNAs, particularly those within EVs, as accessible biomarkers for aggressive B cell lymphoma.
- To highlight how these circulating miRNAs can be developed into reliable liquid biopsy tests.
Main Methods:
- Review of existing literature on miRNA and EV roles in B cell lymphoma.
- Analysis of how aberrant miRNA expression in lymphoma tissues and immune reactions may affect circulating miRNA profiles.
- Focus on miRNAs encapsulated within extracellular vesicles (EVs) due to their stability and role in intercellular communication.
Main Results:
- Aberrant miRNA expression is observed in B cell lymphoma tissues and may be reflected in circulation.
- Extracellular vesicles (EVs) protect miRNAs and facilitate their transport, making them valuable targets.
- Circulating miRNAs, especially within EVs, represent a promising avenue for non-invasive biomarker development.
Conclusions:
- Circulating miRNAs, particularly those associated with extracellular vesicles (EVs), hold significant potential as liquid biopsy biomarkers for aggressive B cell lymphoma.
- These biomarkers could offer a more accessible and dynamic way to monitor disease status and treatment response compared to traditional biopsies.
- Further development of circulating miRNA-based liquid biopsies could revolutionize the management of aggressive B cell lymphoma.
